The study’s final results are consistent with cardiac safety data reported in previous clinical trials that evaluated H IV treatment in the adjuvant setting for HER2-positive EBC [1, 2, 5–7, 9], such as the HERA study [1], and are consistent with the baseline risk factors for CHF as reported in the EU H IV SmPC [4]. This evidence concerns the gene ERBB2 and congestive heart failure.